Persistent left superior vena cava connecting to the left-sided atrium

Summary

Persistent left superior vena cava connecting to the left-sided atrium (MONDO:0020440) is a disease. A subtype of congenital anomaly of superior vena cava — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	persistent left superior vena cava connecting to the left-sided atrium
Mondo ID	MONDO:0020440
Orphanet	99109
UMLS	C5680293
MedGen	1830102
GARD	0019652
Is cancer (heuristic)	no

Also known as: left superior caval vein persisting to the left-sided atrium · persistent left superior caval vein connecting to the left-sided atrium · persistent left SVC connecting to the left-sided atrium

Disease family

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › congenital anomaly of superior vena cava › persistent left superior vena cava connecting to the left-sided atrium

Related subtypes (6): right superior vena cava connecting to left-sided atrium, left superior vena cava persisting to left-sided atrium, absence of innominate vein, subaortic course of innominate vein, agenesis of the superior vena cava, primary superior vena cava aneurysm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.